Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein

Br J Haematol. 2021 Sep;194(6):1085-1090. doi: 10.1111/bjh.17581. Epub 2021 Jun 13.

Authors

Lok-Man Yue¹, David Chau¹, Yok-Lam Kwong¹, Eric Tse¹

Affiliation

¹ Division of Haematology and Medical Oncology, Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.

PMID: 34121173
DOI: 10.1111/bjh.17581

No abstract available

Keywords: anaplastic lymphoma kinase; arsenic trioxide; diffuse large B-cell lymphoma; malignant lymphomas.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anaplastic Lymphoma Kinase / analysis
Anaplastic Lymphoma Kinase / genetics
Antineoplastic Agents / pharmacology*
Arsenic Trioxide / pharmacology*
Cell Line, Tumor
Cell Proliferation / drug effects
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics
Oncogene Proteins, Fusion / analysis
Oncogene Proteins, Fusion / genetics*

Substances

Antineoplastic Agents
Oncogene Proteins, Fusion
oncoprotein CLTCL-ALK
Anaplastic Lymphoma Kinase
Arsenic Trioxide